Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819112 · ClinicalTrials.gov registry record
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 14,799
- Enrollment target
NCT05819112 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 14,799 participants.
The verdict
NCT05819112 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 14,799 participants
- Enrollment target
Study Summary
Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden. Participants hospitalized with an acute medical illness are at increased risk of VTE. This study a non-interventional study which analyzes data already collected in the Optum US clinical database. Its aim is to compare conventional versus extended duration prophylaxis with enoxaparin on the incidence of VTE and bleeding events in participants hospitalized for acute medical illness. The first date of enoxaparin treatment will be the index date.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,799 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05819112
The ClinicalTrials.gov registry entry for NCT05819112 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14,799 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05819112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05819112 about?
NCT05819112 is a clinical study titled "A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness". Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden. Participants hospitalized with an acute medical illness are at increased r...
What is the current status of trial NCT05819112?
This trial is currently terminated. The enrollment target is 14,799 participants. The study started on 2023-04-25. Estimated completion is 2023-12-15.
Who is sponsoring clinical trial NCT05819112?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.